Grifols
Grifols, S.A. is a Spanish multinational pharmaceutical enterprise that specializes in the collection of human blood plasma and the production of plasma-derived protein therapeutics. The company operates through core business segments covering Bioscience, Diagnostic, and Hospital divisions. Its principal product offerings encompass human immunoglobulins, albumin, alpha-1 antitrypsin, clotting factors, and specialized clinical diagnostic reagents. Revenue is driven primarily through the commercial sale of plasma protein therapies and laboratory diagnostics to hospitals and healthcare providers globally. The primary end markets comprise patients suffering from immunodeficiencies, bleeding disorders, and rare chronic diseases. As one of the world's largest producers of plasma-derived medicines, the enterprise maintains an extensive global network of plasma donation centers. Headquartered in Barcelona, Spain, Grifols SA is publicly listed on the Bolsa de Madrid and NASDAQ.
29 of the funds FundTelligence covers report a position in Grifols.
- Legal name
- Grifols SA
- Sector
- Health Care
- Country
- Spain
- Funds holding it
- 29
Funds holding Grifols
- Aktie-Ansvar Europa — Aktie-Ansvar · 2.95 % (full portfolio disclosed, June 2026)
- Nordea European Cross Credit — Nordea Funds · 1.98 % (full portfolio disclosed, July 2026)
- Nordea European Cross Credit ESG Fund — Nordea Funds · 1.7 % (full portfolio disclosed, July 2026)
- Nordea European High Yield Bond — Nordea Funds · 1.55 % (full portfolio disclosed, September 2026)
- UBS Euro High Yield Bond Fund — UBS · 1.5 % (largest positions only, September 2026)
- Nordea European High Yield Opportunities — Nordea Funds · 1.22 % (full portfolio disclosed, September 2026)
- Nordea US High Yield Sustainable Stars Bond Fund — Nordea Funds · 0.83 % (full portfolio disclosed, September 2026)
- Nordea US High Yield Bond — Nordea Funds · 0.75 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 29 funds holding it.